Deep genomic sequencing of endocrine-resistant, ER+, and metastatic breast cancers revealed the presence of ESR1 ligand binding domain mutations (ESR1muts) at a rate of approximately 25% (Toy et al., 2013; Jeselsohn et al., 2014; Robinson et al., 2013). Here, ESR1 is linked to breast carcinoma.